Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody-Reference-Cited by-全球学者库

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Published:2020-09-18 Issue:6510 Volume:369 Page:1505-1509
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Lv Zhe¹²^ORCID,Deng Yong-Qiang³^ORCID,Ye Qing³^ORCID,Cao Lei¹^ORCID,Sun Chun-Yun⁴^ORCID,Fan Changfa⁵^ORCID,Huang Weijin⁶^ORCID,Sun Shihui³^ORCID,Sun Yao¹^ORCID,Zhu Ling¹^ORCID,Chen Qi³^ORCID,Wang Nan¹²^ORCID,Nie Jianhui⁶,Cui Zhen¹²^ORCID,Zhu Dandan¹^ORCID,Shaw Neil¹^ORCID,Li Xiao-Feng³^ORCID,Li Qianqian⁶,Xie Liangzhi⁴⁷⁸^ORCID,Wang Youchun⁶^ORCID,Rao Zihe¹^ORCID,Qin Cheng-Feng³^ORCID,Wang Xiangxi¹²^ORCID

Affiliation:

1. CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.

2. University of Chinese Academy of Sciences, Beijing 100049, China.

3. State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.

4. Beijing Protein and Antibody R&D Engineering Center, Sinocelltech Ltd., Beijing 100176, China.

5. Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China.

6. Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China.

7. Beijing Antibody Research Key Laboratory, Sino Biological Inc., Building 9, Jing Dong Bei Technology Park, No.18 Ke Chuang 10th St, BDA, Beijing, 100176, China.

8. Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China.

Abstract

A steric block to SARS-CoV-2 In response to infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the immune system makes antibodies, many of which target the spike protein, a key player in host cell entry. Antibodies that potently neutralize the virus hold promise as therapeutics and could inform vaccine design. Lv et al. report a humanized monoclonal antibody that protected against SARS-CoV-2 in a mouse model. The cryo–electron microscopy structure, together with biochemical, cellular, and virological studies, showed that the antibody acts by binding to the receptor-binding domain of the spike and blocking its attachment to the host receptor. Science , this issue p. 1505

Funder

Ministry of Science and Technology of the People's Republic of China

National Science Fund for Distinguished Young Scholars

Beijing Municipal Science and Technology Project

the Strategic Priority Research Program

Innovation Fund for Medical Sciences

Innovative Research Group from the NSFC

Ten Thousand Talent Program and the NSFS Innovative Research Group

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary